Seroprevalence of Japanese encephalitis virus-specific antibodies in Australia following novel epidemic spread : protocol for a national cross-sectional study
© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..
INTRODUCTION: Japanese encephalitis virus (JEV) is a mosquito-borne flavivirus that causes encephalitis and other morbidity in Southeast Asia. Since February 2022, geographically dispersed JEV human, animal and vector detections occurred on the Australian mainland for the first time. This study will determine the prevalence of JEV-specific antibodies in human blood with a focus on populations at high risk of JEV exposure and determine risk factors associated with JEV seropositivity by location, age, occupation and other factors.
METHOD: Samples are collected using two approaches: from routine blood donors (4153 samples), and active collections targeting high-risk populations (convenience sampling). Consent-based sampling for the latter includes a participant questionnaire on demographic, vaccination and exposure data. Samples are tested for JEV-specific total antibody using a defined epitope-blocking ELISA, and total antibody to Australian endemic flaviviruses Murray Valley encephalitis and Kunjin viruses.
ANALYSIS: Two analytic approaches will occur: descriptive estimates of seroprevalence and multivariable logistic regression using Bayesian hierarchical models. Descriptive analyses will include unadjusted analysis of raw data with exclusions for JEV-endemic country of birth, travel to JEV-endemic countries, prior JEV-vaccination, and sex-standardised and age-standardised analyses. Multivariable logistic regression will determine which risk factors are associated with JEV seropositivity likely due to recent transmission within Australia and the relative contribution of each factor when accounting for effects within the model.
ETHICS: National Mutual Acceptance ethical approval was obtained from the Sydney Children's Hospitals Network Human Research Ethics Committee (HREC). Local approvals were sought in each jurisdiction. Ethical approval was also obtained from the Australian Red Cross Lifeblood HREC.
DISSEMINATION: Findings will be communicated to participants and their communities, and human and animal health stakeholders and policy-makers iteratively and after final analyses. Understanding human infection rates will inform procurement and targeted allocation of limited JEV vaccine, and public health strategies and communication campaigns, to at-risk populations.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
BMJ open - 14(2024), 2 vom: 07. Feb., Seite e075569 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Winkler, Noni Ella [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 09.02.2024 Date Revised 14.02.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/bmjopen-2023-075569 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368155048 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368155048 | ||
| 003 | DE-627 | ||
| 005 | 20240214233236.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240208s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/bmjopen-2023-075569 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1293.xml |
| 035 | |a (DE-627)NLM368155048 | ||
| 035 | |a (NLM)38326269 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Winkler, Noni Ella |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Seroprevalence of Japanese encephalitis virus-specific antibodies in Australia following novel epidemic spread |b protocol for a national cross-sectional study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.02.2024 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a INTRODUCTION: Japanese encephalitis virus (JEV) is a mosquito-borne flavivirus that causes encephalitis and other morbidity in Southeast Asia. Since February 2022, geographically dispersed JEV human, animal and vector detections occurred on the Australian mainland for the first time. This study will determine the prevalence of JEV-specific antibodies in human blood with a focus on populations at high risk of JEV exposure and determine risk factors associated with JEV seropositivity by location, age, occupation and other factors | ||
| 520 | |a METHOD: Samples are collected using two approaches: from routine blood donors (4153 samples), and active collections targeting high-risk populations (convenience sampling). Consent-based sampling for the latter includes a participant questionnaire on demographic, vaccination and exposure data. Samples are tested for JEV-specific total antibody using a defined epitope-blocking ELISA, and total antibody to Australian endemic flaviviruses Murray Valley encephalitis and Kunjin viruses | ||
| 520 | |a ANALYSIS: Two analytic approaches will occur: descriptive estimates of seroprevalence and multivariable logistic regression using Bayesian hierarchical models. Descriptive analyses will include unadjusted analysis of raw data with exclusions for JEV-endemic country of birth, travel to JEV-endemic countries, prior JEV-vaccination, and sex-standardised and age-standardised analyses. Multivariable logistic regression will determine which risk factors are associated with JEV seropositivity likely due to recent transmission within Australia and the relative contribution of each factor when accounting for effects within the model | ||
| 520 | |a ETHICS: National Mutual Acceptance ethical approval was obtained from the Sydney Children's Hospitals Network Human Research Ethics Committee (HREC). Local approvals were sought in each jurisdiction. Ethical approval was also obtained from the Australian Red Cross Lifeblood HREC | ||
| 520 | |a DISSEMINATION: Findings will be communicated to participants and their communities, and human and animal health stakeholders and policy-makers iteratively and after final analyses. Understanding human infection rates will inform procurement and targeted allocation of limited JEV vaccine, and public health strategies and communication campaigns, to at-risk populations | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Epidemiology | |
| 650 | 4 | |a Surveys and Questionnaires | |
| 650 | 4 | |a VIROLOGY | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Koirala, Archana |e verfasserin |4 aut | |
| 700 | 1 | |a Kaur, Guddu |e verfasserin |4 aut | |
| 700 | 1 | |a Prasad, Shayal |e verfasserin |4 aut | |
| 700 | 1 | |a Hirani, Rena |e verfasserin |4 aut | |
| 700 | 1 | |a Baker, Jannah |e verfasserin |4 aut | |
| 700 | 1 | |a Hoad, Veronica |e verfasserin |4 aut | |
| 700 | 1 | |a Gosbell, Iain B |e verfasserin |4 aut | |
| 700 | 1 | |a Irving, David O |e verfasserin |4 aut | |
| 700 | 1 | |a Hueston, Linda |e verfasserin |4 aut | |
| 700 | 1 | |a O'Sullivan, Matthew Vn |e verfasserin |4 aut | |
| 700 | 1 | |a Kok, Jen |e verfasserin |4 aut | |
| 700 | 1 | |a Dwyer, Dominic E |e verfasserin |4 aut | |
| 700 | 1 | |a Macartney, Kristine |e verfasserin |4 aut | |
| 700 | 0 | |a Australian Japanese Encephalitis Virus Serosurvey Group |e verfasserin |4 aut | |
| 700 | 0 | |a Australian Japanese encephalitis virus serosurvey group |e verfasserin |4 aut | |
| 700 | 1 | |a Lambert, Stephen |e investigator |4 oth | |
| 700 | 1 | |a Williamson, Deborah |e investigator |4 oth | |
| 700 | 1 | |a Baker, Jannah |e investigator |4 oth | |
| 700 | 1 | |a Snelling, Tom |e investigator |4 oth | |
| 700 | 1 | |a Glasgow, Keira |e investigator |4 oth | |
| 700 | 1 | |a Hope, Kirsty |e investigator |4 oth | |
| 700 | 1 | |a Luscombe, Chloe |e investigator |4 oth | |
| 700 | 1 | |a Notaras, Adriana |e investigator |4 oth | |
| 700 | 1 | |a Baldwin, Zoe |e investigator |4 oth | |
| 700 | 1 | |a Case, Jennifer |e investigator |4 oth | |
| 700 | 1 | |a Thomson, Tilda |e investigator |4 oth | |
| 700 | 1 | |a Marsland, Madeleine |e investigator |4 oth | |
| 700 | 1 | |a O'Brien, Helen |e investigator |4 oth | |
| 700 | 1 | |a Deborah Friedman, N |e investigator |4 oth | |
| 700 | 1 | |a Carroll, Heidi |e investigator |4 oth | |
| 700 | 1 | |a Holland, Candice |e investigator |4 oth | |
| 700 | 1 | |a Kitchener, Scott |e investigator |4 oth | |
| 700 | 1 | |a Ratsch, Angela |e investigator |4 oth | |
| 700 | 1 | |a Chor, Josette |e investigator |4 oth | |
| 700 | 1 | |a Sykes, Alice |e investigator |4 oth | |
| 700 | 1 | |a Khandaker, Gulam |e investigator |4 oth | |
| 700 | 1 | |a Smoll, Nicolas |e investigator |4 oth | |
| 700 | 1 | |a Walker, Jacina |e investigator |4 oth | |
| 700 | 1 | |a Flynn, Liam |e investigator |4 oth | |
| 700 | 1 | |a Krause, Vicki |e investigator |4 oth | |
| 700 | 1 | |a Williams, Aleena |e investigator |4 oth | |
| 700 | 1 | |a Hinchcliff, Alexandra |e investigator |4 oth | |
| 700 | 1 | |a Nelson, Jane |e investigator |4 oth | |
| 700 | 1 | |a Currie, Bart |e investigator |4 oth | |
| 700 | 1 | |a Flood, Louise |e investigator |4 oth | |
| 700 | 1 | |a Beazley, Rebecca |e investigator |4 oth | |
| 700 | 1 | |a Spurrier, Nicola |e investigator |4 oth | |
| 700 | 1 | |a Hayward, Carmen |e investigator |4 oth | |
| 700 | 1 | |a Worley, Paul |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t BMJ open |d 2012 |g 14(2024), 2 vom: 07. Feb., Seite e075569 |w (DE-627)NLM215724372 |x 2044-6055 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2024 |g number:2 |g day:07 |g month:02 |g pages:e075569 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/bmjopen-2023-075569 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2024 |e 2 |b 07 |c 02 |h e075569 | ||